CSL has unveiled the future of plasma manufacturing in Australia with the opening of their $900 million Plasma Fractionation Facility in Victoria, the largest of its kind in the Southern Hemisphere. This is part of a $2 billion-plus capital investment program CSL currently has underway in Australia.

The new state-of-the-art facility in Broadmeadows allows CSL’s manufacturing site to process up to 9.2 million plasma equivalent litres per annum. This is a nine-fold increase on current capacity for the site and will help meet the increasing demand for plasma-based, life-saving therapies for patients around the world.

Plasma-derived therapies treat those with immunodeficiencies, neurological disorders, shock and burns. They are used in operating rooms around the world for transplant patients, surgical patients and cancer patients.

The Broadmeadows Plasma Fractionation Facility is part of CSL’s current $2 billion dollar plus investment programme focused on Australia, which also includes a next generation influenza vaccine manufacturing facility for CSL Seqirus at Tullamarine, and CSL’s new global headquarters and R&D facilities located in the heart of Melbourne’s biomedical precinct.

The new CSL facility will process domestic plasma from Australian, New Zealand, Taiwan, Hong Kong and Malaysian donor plasma, in addition to commercially sourced plasma through CSL Plasma (a subsidiary of CSL), one of the world’s largest collectors of human plasma.

The new Australian Plasma Fractionation Facility has received approval by the Australian Therapeutic Goods Administration and is expected to be fully operational from early 2023.